University of Pennsylvania

ScholarlyCommons
Health Care Management Papers

Wharton Faculty Research

8-8-2013

Effects of Medicaid on Clinical Outcomes
Ari B. Friedman
University of Pennsylvania

Follow this and additional works at: https://repository.upenn.edu/hcmg_papers

Recommended Citation
Friedman, A. B. (2013). Effects of Medicaid on Clinical Outcomes. The New England Journal of Medicine,
369 (6), 582-582. http://dx.doi.org/10.1056/NEJMc1306867

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/hcmg_papers/57
For more information, please contact repository@pobox.upenn.edu.

Effects of Medicaid on Clinical Outcomes
Keywords
Health Care Costs, Health Status, Humans, Insurance Coverage, Medicaid

This journal article is available at ScholarlyCommons: https://repository.upenn.edu/hcmg_papers/57

correspondence

and the results of the meta-analysis less relevant
in the context of the hypothesis that ongoing
treatment with azithromycin would lead to sudden death from cardiovascular causes, as suggested by the study involving Medicaid beneficiaries by Ray et al.
Brass argues that our conclusion is not supported by our results. Our conclusion was carefully phrased with the use of noncausal terminology and is an accurate reflection of our findings
that exposure was not associated with an increased risk of the outcome. This reflects a statistical estimate that best fits the data, given the
imposed statistical model.
However, like Brass, we think it is important
to note that only a moderate-to-high relative increase in the risk of death from cardiovascular
causes (>55%) can be ruled out with a high degree of certainty; this was explicitly stated in the
Discussion section of our article.
Nevertheless, Brass raises important questions about terminology and the interpretation
of statistical measures in medical research. We
believe these questions extend far beyond the
context of our specific study.
Henrik Svanström, M.Sc.
Björn Pasternak, M.D., Ph.D.
Anders Hviid, Dr.Med.Sci.
Statens Serum Institut
Copenhagen, Denmark
htr@ssi.dk

Dr. Mosholder and a Colleague Reply: McMurray and Jhund correctly point out that mortality was not increased in long-term placebo-controlled trials of azithromycin for the prevention of
atherosclerotic cardiac events. However, we draw
only very limited reassurance from these data because of the design of the trials. In the six trials
analyzed by Baker and Couch, the duration of
azithromycin exposure relative to the follow-up
time was different from that in the study by Ray
et al., because patients received azithromycin only
during a small fraction of the total days of follow-up time. For example, in the Azithromycin
and Coronary Events Study reported by Grayston
et al., patients received azithromycin once a week
for a year, and the median time to follow-up was
3.9 years. Given that Ray et al. found a risk only
on days with azithromycin use (days 1 through
5 after the prescription), these long-term trials on
cardiovascular prevention, as they were analyzed,
are not suitable for assessing such an association
with the rate of death from cardiovascular causes.
The comments by Brass reinforce the importance of considering not only the point estimate
for a measure of risk, but also its confidence
interval.
Andrew D. Mosholder, M.D., M.P.H.
Sumathi Nambiar, M.D., M.P.H.
Food and Drug Administration
Silver Spring, MD
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Effects of Medicaid on Clinical Outcomes
To the Editor: In a comprehensive and careful
follow-up to their previous analysis,1 Baicker et al.
(May 2 issue)2 report on the effects of insurance
coverage on health care and health outcomes in
the Oregon Medicaid lottery experiment after approximately 2 years. Their instrumental-variable
analysis is the next best thing to a randomized,
controlled trial, since the instrument — in this
case, winning a lottery for Medicaid coverage —
satisfies the large-sample properties of being
correlated to treatment and not being correlated
to the outcomes of interest (e.g., health care utilization and outcomes) except through its effect
on treatment.3
n engl j med 369;6

The financial effects on the lottery winners
were not trivial. They received an in-kind benefit valued at one third to two thirds of their
household income, their out-of-pocket spending was reduced by 39% ($215), and catastrophic expenditures were reduced by 81%. These
financial consequences could have a direct effect on self-reported depression, other mental
health conditions, and possibly other outcomes. It
is telling that self-reported happiness increased
in the first year after winning the lottery, but
not in the second.1,2,4 Awarding lottery winners
equivalents of cash prizes (worth approximately
$6,600 each) rather than Medicaid might have
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improved their health outcomes and well-being
even more.
Joel W. Hay, Ph.D.
University of Southern California
Los Angeles, CA
jhay@usc.edu
No potential conflict of interest relevant to this letter was reported.
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To the Editor: Baicker et al. provide high-quality evidence of the failure of insurance to promote physical health even among the insured.
One cause may be that insurers do not cover costeffective programs that reach beyond the threshold of the physician’s office to change patient
behavior,1 support patients at home,2 and alter
systems of delivery.3
Even if they suggest that they support such
interventions, insurers underinvest in them. For
instance, for persons with diabetes, my own
(generous) insurance covers only a handful of
visits with a dietitian, and it offers neither telephone-based reminders nor counseling on diet
or exercise — far less than effective methods
require.4
Public and private payers have tried to compensate hospitals and physicians according to
performance. Results have been decidedly mixed.5
The reason may be not what they pay or how
they pay it, but to whom. Insurers should be
rewarded and penalized on the basis of comprehensive health outcomes (e.g., mortality, not just
blood-pressure levels).
Insurers determine where funds flow. If we
want the health system to care more about
population health, we should make sure that
insurers do too.

To the Editor: The abstract in the article by
Baicker et al. states that “Medicaid coverage generated no significant improvements in measured
physical health.” This is a misleading summary
of the data reported in their article. The best estimates are that the Medicaid group had better
outcomes than the control group according to
most measures (see Table 2 of the article). The
problem is that these findings are not statistically significant.
So, the effects might have been zero. That is
not the same as saying that they were zero, or
even that they were small. Buried toward the end
of the article is the statement, “The 95% confidence intervals for many of the estimates of ef- Ari B. Friedman, B.A.
fects . . . include changes that would be con- University of Pennsylvania
sidered clinically significant.”
Philadelphia, PA
Nevertheless, almost all the article, the relat- abfriedman@gmail.com
No potential conflict of interest relevant to this letter was reed editorial,1 and related news reports, opinion
pieces, and online discussions proceeded as if ported.
the effects had been found to be zero.
1. Volpp KG, Troxel AB, Pauly MV, et al. A randomized, conIf one objects, on the basis of a lack of statis- trolled trial of financial incentives for smoking cessation. N Engl
J Med 2009;360:699-709.
tical certainty, to the simple summary that the 2. Johansson P, Sadigh S, Tillgren P, Rehnberg C. Non-pharmaMedicaid group had better outcomes, then one ceutical prevention of hip fractures — a cost-effectiveness analyshould describe the substantive meaning of the sis of a community-based elderly safety promotion program in
Sweden. Cost Eff Resour Alloc 2008;6:11.
confidence interval. An honest summary is that 3. Insurers’ medical loss ratios and quality improvement spendit is quite likely there were positive effects, ing in 2011. New York: Commonwealth Fund, 2013 (http://www
though it is possible that they were zero or .commonwealthfund.org/~/media/Files/publications/Issue%20
Brief/2013/Mar/1671_Hall_how_insurers_MLRs_spending_
negative.
differ_ib.pdf ).
4. Roux L, Pratt M, Tengs TO, et al. Cost effectiveness of comRoss Boylan, Ph.D.
University of California, San Francisco
San Francisco, CA
ross@biostat.ucsf.edu
No potential conflict of interest relevant to this letter was reported.
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The Authors Reply: We appreciate the attention
given to our study and agree with many of the
comments. Our study indeed does not speak directly to the effects of different types of insurance or of alternatives such as cash grants; these
are important topics for future research.
Statistical precision is crucial to interpretation
of the findings. The reported confidence intervals
do not allow us to reject the null hypothesis that
there was no effect of Medicaid on blood-pressure, cholesterol, or glycated hemoglobin levels
— but they are also consistent with Medicaid
improving (or harming) these outcomes. Empirical estimates always come with uncertainty.
A key question is what effect sizes our findings
rule out, and how these compare with findings
from previous studies of the effect of health insurance or with expectations based on available
treatments.
In some cases, we can reject effect sizes seen
in previous studies. For example, we can reject
decreases in diastolic blood pressure of more
than 2.7 mm Hg (or 3.2 mm Hg in patients with
a preexisting diagnosis of hypertension) with
95% confidence. Quasi-experimental studies of
the 1-year effect of Medicaid showed decreases
in diastolic blood pressure of 6 to 9 mm Hg.1,2
In other cases, our confidence intervals do
not rule out the health improvements one might
expect given our estimate of the effect of Medicaid on medication use. For example, as noted in
our article, given our estimate of the increase in
the use of diabetes medication because of Medicaid, the clinical literature would predict a de-

crease in the average glycated hemoglobin level
of 0.05 percentage points, an effect that is well
within our 95% confidence interval.
We assessed conditions for which treatments
exist that were effective within 2 years (our study
period), but power is always constrained by sample size and is further reduced here by the imperfect take-up rates of Medicaid and lack of
baseline clinical measures. We took several
steps to increase power. Our study examined
subgroups in which one might expect larger
Medicaid effects (older persons and those with
preexisting conditions) and we combined measures using the composite Framingham risk
score. In none of these cases did we find statistically significant effects of Medicaid on
physical health. We did find substantial and
significant improvements in depression and financial well-being, as well as an increased use of
health care.
Katherine Baicker, Ph.D.
Harvard School of Public Health
Boston, MA
kbaicker@hsph.harvard.edu

Amy N. Finkelstein, Ph.D.
Massachusetts Institute of Technology
Cambridge, MA
Since publication of their article, the authors report no further potential conflict of interest.
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Case 12-2013: A Woman with Pulmonary Infiltrates
and Respiratory Failure
To the Editor: The Case Record presented by
Hunt et al. (April 18 issue)1 describes a previously healthy 18-year-old woman with severe
pneumonia due to herpes simplex virus type 1
(HSV-1). It was speculated that the infection may
have been acquired from her new boyfriend, and
the HSV-1 infection was more likely to be primary than due to reactivation. The large number
of infected cells in the bronchoalveolar-lavage
fluid, the appearance of the alveolar cells on cytologic examination, and the rapid response to

n engl j med 369;6

therapy with acyclovir were cited as reasons for
the diagnosis of probable primary HSV infection.
Determination of the patient’s HSV IgG and IgM
status would have further helped address this issue. Although serum antibody against HSV-1 was
positive, the type of antibody was not mentioned.
A positive IgM (with negative IgG) would suggest
primary infection, whereas a positive IgG (with
negative IgM) would indicate HSV reactivation,
either of which may have led to pneumonia and
the crusted lesion on the patient’s lip. Also, clar-
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